摘要
目的:评价超声引导超抗原类免疫增强剂高聚生,瘤区注射在肝癌介入治疗中的临床应用效果。方法:22例肝癌治疗前均获得明确的组织病理学诊断,并于高聚生瘤区注射前接受超声引导经皮微波凝固治疗,在微波治疗结束后3天、7天、30天、3个月、6个月、9个月、12个月共7个时间点于超声引导下行高聚生瘤区注射,用药剂量为2000U/次。结果:瘤区标本免疫组化研究显示高聚生治疗后瘤区观察的各种抗肿瘤免疫细胞均较治疗前显著增多(P<0.01),局部免疫状态得到改善。按Kaplan-Meier法求得患者1年生存率为93.8%,1年未复发率为81.9%。结论:该方法作为一种新的高聚生给药途径,安全性好,效果显著,值得临床进一步研究、探讨。
Objective:To study the clinical value of intrahepatic injections of Gaojusheng for interventional treatment of liver carcinoma.Methods:By means of ultrasonic guide,we have given the intrahepatic injections of Gaojusheng for22cases of liver carcinoma,which had been diagnosed by pathology,at day3?day7?day30?month3?month6?month9?and month12after microwave coagulation therapy.The dose of each injection is2000U.Results:Imunohistochemical staining of CD-positive immune cells after Gaojusheng injection demonstrate significant difference in the degree of infiltration at tumour site with that before Gaojusheng injection (P<0.01).The yearly survival rate and the yearly unrecurrence rate,which were determined by the Kaplan-Meier method,are93.8%and81.9%respectively.Conclusion:We think that intrahepatic injections of Gaojusheng is not only a new way for treatment of liver carcinoma,but a safe and effective pro-cedure as well.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2002年第11期797-798,801,共3页
Chinese Journal of Clinical Oncology
